Splenectomy normalizes hematocrit in murine polycythemia vera

PLoS ONE

Volumn 4, Issue 9, 2009, Pages

  Mo, Jan Rung ^a   Mathur, Anjili ^a   Angagaw, Minilik ^a   Zhao, Shuxia ^a   Wang, Yuxun ^a   Gargano, Diana ^a   DiBacco, Alessandra ^a   Bachman, Eric S ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; JANUS KINASE 2; JAK2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; ERYTHROCYTOSIS; HEMATOCRIT; HISTOPATHOLOGY; MOUSE; MYELOFIBROSIS; NONHUMAN; OSTEOSCLEROSIS; PATHOGENESIS; PHENOTYPE; POLYCYTHEMIA VERA; SPLENECTOMY; SPLENOMEGALY; ALLELE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BONE MARROW; C57BL MOUSE; GENETICS; METABOLISM; METHODOLOGY; MUTATION; SPLEEN;

MURINAE; MUS;

ALLELES; ANIMALS; BONE MARROW; BONE MARROW TRANSPLANTATION; ERYTHROPOIETIN; HEMATOCRIT; JANUS KINASE 2; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MUTATION; PHENOTYPE; POLYCYTHEMIA VERA; SPLEEN; SPLENECTOMY;

EID: 70349653467     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007286     Document Type: Article

References (27)

1. Results of a prospective randomized trial of early splenectomy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Cancer, 1984. 54(2): 333-8.
2. Mesa RA, Elliott MA, Tefferi A (2000) Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia. Blood Rev 14: 121-129.
3. Gilbert HS (2003) Modern treatment strategies in polycythemia vera. Semin Hematol 40(1 Suppl 1): 26-29.
4. Wasserman LR, Gilbert HS (1963) Surgery in Polycythemia Vera. N Engl J Med 269: 1226-1230.
5. Cunningham SC, Napolitano LM (2004) Splenectomy for massive splenomegaly of polycythemia vera. Am J Surg 188: 94-95.
6. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148.
7. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397.
8. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061.
9. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790.
10. Zhao R, Xing S, Li Z, Fu X, Li Q, et al. (2005) Identification of an acquired Jak2 mutation in polycythemia vera. J Biol Chem 280: 22788-22792.
11. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, et al. (2007) TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21: 1658-1668.
12. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, et al. (2006) Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107: 4274-4281.
13. Liu Y, Pop R, Sadegh C, Brugnara C, Haase VH, et al. (2006) Suppression of Fas-FasL co expression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood 108: 123-133.
14. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, et al. (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108: 1652-1660.
15. Raff RF, Loughran TP Jr, Graham T, Pepe M, Johnston B, et al. (1993) Splenectomy does not enhance engraftment of DLA-nonidentical marrow transplants. Exp Hematol 21: 385-387.
16. McDonald TP, Clift RE, Cottrell MB (1992) Large, chronic doses of erythropoietin cause thrombocytopenia in mice. Blood 80: 352-358.
17. Mathur A, Mo JR, Kraus M, O'Hare E, Sinclair P, et al. (2009) An inhibitor of Janus kinase 2 prevents polycythemia in mice. Biochem Pharmacol 78: 382-389.
18. Morgan KJ, Gilliland DG (2008) A role for Jak2 mutations in myeloproliferative diseases. Annu Rev Med 59: 371-380.
19. V617F causes myeloproliferative disorders in mice. Blood 111: 5109-5117.
20. Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC (2007) The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype. Eur J Haematoloyg 79: 508-515.
21. de Haan G, Engel C, Dontje B, Nijhof W, Loeffler M (1994) Mutual inhibition of murine erythropoiesis and granulopoiesis during combined erythropoietin, granulocyte colony-stimulating factor, and stem cell factor administration: in vivo interactions and dose-response surfaces. Blood 84: 4157-4163.
22. Messinezy M, Macdonald LM, Nunan TO, Westwood NB, Chinn S, et al. (1997) Spleen sizing by ultrasound in polycythemia and thrombocythaemia; comparison with SPECT. Br J Haematol 98: 103-107.
23. Hsieh PP, Olsen RJ, O'Malley DP, Konoplev SN, Hussong JW, et al. (2007) The role of Janus kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. Mod Pathol 20: 929-935.
24. Agool A, Schot BW, Jager PL, Vellenga E (2006) 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nuc Med 47: 1592-1598.
25. Tefferi A (2003) Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc 78: 174-194.
26. Cadili A, de Gara C (2008) Complications of splenectomy. Am J Med 121: 371-375.
27. Scott LM (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356: 459-468.